Press Releases Genelux Corporation

Equities

GNLX

US36870H1032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.71 ^USD	+2.26%		+3.44%	-80.66%

May. 24	Top Midday Decliners	MT
May. 24	Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants	May. 24	GL
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants	May. 24	AQ
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants	May. 23	GL
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates	May. 09	GL
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Apr. 01	GL
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer	Nov. 27	GL
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates	Nov. 14	GL
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-09-14	GL
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference	23-09-07	GL
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference	23-09-07	AQ
Genelux Corporation Announces New Chief Financial Officer	23-08-28	GL
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates	23-08-14	GL
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates	23-08-14	AQ
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023	23-08-02	GL
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023	23-08-02	AQ
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires	23-07-20	GL
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires	23-07-20	AQ
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology	23-07-10	GL
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC	23-06-29	GL
Genelux Corporation Set to Join the Russell 3000 and Russell 2000 Indexes Effective June 26, 2023	23-06-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Genelux Corporation

Equities

GNLX

US36870H1032

Press Releases

Filters